Preparation for determining pyrimidine metabolic capacity

Details Preparation for determining pyrimidine metabolic capacity Preparation for determining pyrimidine metabolic capacity

2002-08-01

2009-02-10

Jones, D. L (Department: 1618)

Drug, bio-affecting and body treating compositions

Radionuclide or intended radionuclide containing; adjuvant...

In an organic compound

C424S001110, C424S001650, C424S001730, C424S009200

Reexamination Certificate

active

07488466

ABSTRACT:
The present invention provide a method for measuring and assessing the capacity in an individual subject to metabolize a variety of fluorouracil drugs, such as 5-fluorouracil, which are degraded in the pyrimidine metabolic pathway, and a preparation useful for the measurement and assessment. The present invention can be carried out by: administering a preparation for determining pyrimidine metabolic capacity comprising as an active ingredient a pyrimidine compound or pyrimidine metabolic compound that acts as a substrate for a pyrimidine metabolizing enzyme, in which at least one of the carbon, oxygen, and nitrogen atoms is labeled with an isotope; and assessing in vivo pyrimidine metabolic capacity based on the behavior of an excreted metabolite.

REFERENCES:
patent: 5077034 (1991-12-01), Kassis et al.
patent: 5248771 (1993-09-01), Dougan
patent: 5944670 (1999-08-01), Katzman
patent: 6232448 (2001-05-01), Yoshikubo et al.
Creasey et al., “The metabolism of uracil-2-14C and the granulocyte response to endotoxin as indicators of the toxicity produced in patients receiving 5-fluorouracil,”Clinical Pharmacology and Therapeutics, vol. 8, No. 2:273-282, 1967.
Fernandez-Salguero et al., “Correlation between catalytic activity and protein content for the polymorphically expressed dihydropyrimidine dehydrogenase in human lymphocytes,”Biochemical Pharmacology, vol. 50, No. 7:1015-1020 (1995).
Fleming et al., “Correlation between Dihydropyrimidine Dehydrogenase Activity in Peripheral Mononuclear Cells and Systemic Clearance of Fluorouracil in Cancer Patients,” Cancer Research, vol. 52:2899-2902 (May 15, 1999).
Johnson, et al., “Semi-automated radioassay for determination of dihydropyrimidine dehydrogenase (DPD) activity; Screening cancer patients for DPD deficiency, a condition associated with 5-fluorouracil toxicity,”Journal of Chromatography B, vol. 696:183-191 (1997).
Sumi et al., “Automated screening system for purine and pyrimidine metabolism disorders using high-performance liquid chromatography,”Journal of Chromatography B, vol. 672:233-239 (1995).
Sumi et al., “Possible prediction of adverse reactions to fluorouracil by the measurement of urinary dihydrothymine and thymine,”Int'l. Journal of Molecular Medicine, vol. 2:477-482 (1998).
Ma et al., “Study of the Use of Fluorouracil Suppositories as Supplementary Presurgical Chemotherapy For Rectal Cancer” China Pharmaceutical Journal, 29:7 pp. 1-9, Jul. 1994.
Ma Lie, Wang, Yi-chun, Supplemental suppository fluorouracil in chemotherapy of rectal cancer, 29 (7); pp. 133-435, Jul. 1994, (non-English).
First Office Action from Patent Office of China for Chinese Application 02806426.7 dated Nov. 19, 2004, (non-English).
Visser et al., “An Optimized Synthesis of18F-Labelled 5-Fluorouracil and a Reevaluation of Its Use as a Prognostic Agent,”European Journal of Nuclear Medicine15(5):225-229 (1989).
Tanigawa et al., “Simple and Rapid Quantitative Assay of13C-labelled Urea in Human Serum Using Liquid Chromatoghapy-Atmospheric Pressure Chemical Ionization Mass Spectrometry,”Journal of Chromatography B.: Biomedical Applications683(2):135-142 (1996).
Visser et al., “18F-Radiopharmacokinetics of [18F]-5-Fluorouracil in a Mouse Bearing Two Colon Tumors with a Different 5-Fluorouracil Sensitivity: A Study for a Correlation with Oncological Results,”Nuclear Medicine and Biology23(3):333-342 (1996).
Harris et al., “Relationship Between Dihydropyrimidine Dehydrogenase Activity and Plasma 5-Fluorouracil Levels with Evidence for Circadian Variation of Enzyme Activity and Plasma Drug Levels in Cancer Patients Receiving 5-Fluorouracil by Protracted Continuous Infusion,”Cancer Research50(1):197-201 (1990).
European Search Report for European Application No. 02705125.9-2123 (PCT/JP0202351) dated May 21, 2007.

Affiliated with

Also associated with

Rating

Preparation for determining pyrimidine metabolic capacity does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Preparation for determining pyrimidine metabolic capacity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Preparation for determining pyrimidine metabolic capacity will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4134658